LISAvienna: “Start-up Labs at the Vienna BioCenter” - Business Treff Review

On April 3, 2019, the Vienna Business Agency presented details and information about the application procedure for the new Start-up Labs at the Vienna BioCenter. During the event, Boehringer Ingelheim also introduced the “BI Innovation Prize – Austria” program that is linked to the Start-up Labs. We were overwhelmed by the interest sparked by this news.

In December 2019, a total of 70 bench and 30 office workplaces will be available to life science start-ups in Vienna. Apply as of May 1, 2019!

Start-ups will be able to rent affordable and flexible workplaces totaling more than 1,100m² in the heart of the Vienna BioCenter and enjoy joint use of the equipment and facilities provided. This offer is intended primarily for start-ups carrying out research and development in the fields of biochemistry, biomedicine, biotechnology, genetics, molecular biology and pharmaceutics.

The start-up labs will feature a range of equipment, including:

  • Centrifuges, vortexers, mixers & heat blocks, scales & pH meters
  • PCR, SDS-PAGE & agarose gel electrophoresis, imaging
  • Bacterial incubators & shakers
  • BSL2 cell culture facilities, including sterile workbenches, CO2 incubators & microscopes
  • Reagent-grade distilled water, liquid nitrogen
  • -80°C & -20°C freezers, fridges and storage for material & consumables
  • Autoclave, dish washer, ice machine
  • Information technology & telecommunications

Additional details and information on how to apply and whom to contact at the Vienna Business Agency are available here.

BI Innovation Prize – Austria

Boehringer Ingelheim supports selected start-ups by paying their lab and office rent in the new space available at the Vienna BioCenter for up to 12 months. Companies interested in this offer are invited to apply after being granted access to the Start-up Labs. Approach Boehringer Inglheim with a non-confidential summary of your business plan (2 pages) or a pitch slide deck (5-10 slides). Start-ups whose applications have been approved will also gain access to Boehringer Ingelheim’s extensive biopharmaceutical expertise, if desired. Further background information is included in the slides.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)